Journal of Thoracic Oncology

Papers
(The H4-Index of Journal of Thoracic Oncology is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response311
Board of Directors208
PP01.172 It's Never Too Late To Quit201
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study190
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis151
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis131
In This Issue123
Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?122
Comment on “MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC”121
EP.02A.02 The Stroma Cell Function in the Border Region Between Lung Cancer and Normal Lung119
EP.09.05 Efficacy and Prognostic Factors of Radiotherapy in Brain Metastases From Non-Small Cell Lung Cancer Patients:A Retrospective Study118
P1.11.03 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis117
OA01.04 Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk117
P2.15.17 Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline116
P2.15.15 Impact of Palliative Care in Patients With Non-Small Cell Lung Cancer and Brain Metastases: A Retrospective Quality Analysis108
P1.11.04 Prediction of Overall Survival in Lung Cancer Patients With Different Organ Metastases: A SEER Population-Based Cohort Study102
EP.02.05 Three-Dimensional Visualization of Spreading Tumor Cell Through Air Spaces (STAS) Using High Resolution Phase-Contrast Imaging Method101
P3.16.09 A Study of Testing Knowledge Regarding Lung Cancer Screening Among General Population and Caregivers98
EP.13.08 Early Hospitalization During Chemoradiation for Limited-Stage Small Cell Lung Cancer Is Associated With Inferior Survival97
EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC94
P3.12.09 Efficacy of Tepotinib Against Non-Adenocarcinoma MET Exon 14 Skipping NSCLC: A Subanalysis of the REAL-MET Study93
EP.16.07 Addressing Unmet Needs of the Lung Cancer Community: The Journey to Find and Implement Mind Over Matter91
EP.04.42 Alunghive: Autonomous Registry and Analytics System to Transform Clinical Workflow and Enable Multicenter Lung Cancer Screening Research91
EP.13.20 Stereotactic Body Radiotherapy for Limited-Stage Small Cell Lung Cancer: Outcomes From a Single-Institution Retrospective Study87
P3.12.43 A Phase II Study of Sunvozertinib Combined With Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations85
P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes83
P2.02.33 Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer82
MA06.01 Real-World Outcomes of First-Line Immunotherapy Intensification of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC)81
EP.17.29 Real-World Effectiveness of Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Without Oncogenic Driver Alteration81
P1.17.27 Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics From CT Scans80
OA10.02 Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study80
P2.10.10 Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery With Clinically Validated Tumor Selective Linker Payload77
P2.08.44 Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-Small Cell Lung Cancer: A Real-World Study76
EP.06.78 T Lymphocyte Subpopulations as Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Anti-Pd(L)1 Inhibitors75
EP.05.03 Analysis of Left Upper Pulmonary Arterial Bronchial Concomitant Consistency Based on Three-Dimensional Reconstruction71
P3.01.17 Age-Sex Disparities in Global Burden and Trend of Lung Cancer and Its Attributable Risk Factors in the United Kingdom From 1990-202170
EP.11.14 Impact of Bone Metastases on the Efficacy of First-Line Immunotherapy in Advanced NSCLC: An Analysis From a Prospective Real-World Study69
EP.15.07 Living With Lung Cancer-A Qualitative Exploration of Its Psychosocial Impact66
EP.12.38 Firmonertinib(160Mg) Combined With Chemotherapy as First-Line Treatment for Advanced NSCLC Patients With EGFR Mutations and Cns Metastases66
PT2.16.04 Advancing Lung Cancer Advocacy in Low- and Middle-Income Countries65
PT1.03.02 Single-Cell Profiling of Tumor Lineage Plasticity and the Immune Microenvironment in Transformed Small Cell Lung Cancer64
P3.12.36 Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan64
P3.13.02 The Effectiveness of Anatomical Versus Non-Anatomical Resection for Treatment of Small Cell Lung Carcinoma64
P1.17.63 Docetaxel and Docetaxel Plus Ramucirumab Demonstrate Similar Real-World Overall Survival: A Contemporary Analysis64
EP.01.19 Characteristics of Lung Cancer in Never- and Light-Smokers: A Retrospective Study From Greece63
P1.17.17 Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC63
PPD01.03: Real World Data On Lung Cancer Detection In A High-Risk Population In A Colombian Insurance Company62
FBXO11 Mediates PARP Inhibitor Resistance in Small-Cell Lung Cancer62
Serum microRNAs are Associated with Treatment Response and Disease Progression in Limited Stage Small Cell Lung Cancer62
EP.08D.06 Neoadjuvant Chemoimmunotherapy Does Not Increase Postoperative Morbidity of Pneumonectomy in NSCLC Patients: A Multi-Center Psmanalysis61
PP01.21: Evaluating the Accuracy & Reproducibility of ChatGPT Models in Answering Patient’s Lung Cancer Queries61
P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study60
P1.08C.05 The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study60
EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib59
P2.17B.02 Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols58
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients58
EP.07F.06 Prospective Study of Breath Hold During SBRT Treatment of the Lung: Analysis Reliability of Surface Guidance Alone for Breath Hold57
EP.04A.01 Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation57
0.17639493942261